7557-34-8 Usage
Description
(R)-2-Benzyloxycarbonylamino-3-(2-fluoro-phenyl)-propionic acid is a complex organic compound with a molecular formula of C19H18FNO4. It is a derivative of amino acids, characterized by the presence of a benzyl group, a fluoro-phenyl group, and a propionic acid moiety. (R)-2-Benzyloxycarbonylamino-3-(2-fluoro-phenyl)-propionic acid holds promise in pharmaceutical research and drug development due to its unique structural features and potential biological activities. Its stereochemistry and functional groups make it a valuable intermediate in the synthesis of novel compounds for the potential treatment of various medical conditions. Further studies and research are required to fully comprehend its pharmacological properties and potential therapeutic applications.
Uses
Used in Pharmaceutical Research:
(R)-2-Benzyloxycarbonylamino-3-(2-fluoro-phenyl)-propionic acid is used as a valuable intermediate in pharmaceutical research for the synthesis of novel compounds. Its unique structural features and potential biological activities make it a promising candidate for the development of new drugs to treat various medical conditions.
Used in Drug Development:
In the field of drug development, (R)-2-Benzyloxycarbonylamino-3-(2-fluoro-phenyl)-propionic acid is utilized as a key component in the creation of new pharmaceuticals. Its stereochemistry and functional groups contribute to the design and synthesis of innovative drugs with potential therapeutic benefits.
Used in Medical Condition Treatment:
(R)-2-Benzyloxycarbonylamino-3-(2-fluoro-phenyl)-propionic acid is used as a building block in the development of treatments for various medical conditions. Its potential applications in pharmaceutical research and drug development make it a significant compound in the quest for new therapies and cures.
Check Digit Verification of cas no
The CAS Registry Mumber 7557-34-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,5,5 and 7 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 7557-34:
(6*7)+(5*5)+(4*5)+(3*7)+(2*3)+(1*4)=118
118 % 10 = 8
So 7557-34-8 is a valid CAS Registry Number.
7557-34-8Relevant articles and documents
Synthesis, in vitro biological activity, hydrolytic stability and docking of new analogs of BIM-23052 containing halogenated amino acids
Danalev, Dancho,Borisova, Desislava,Yaneva, Spaska,Georgieva, Maya,Balacheva, Anelia,Dzimbova, Tatyana,Iliev, Ivan,Pajpanova, Tamara,Zaharieva, Zdravka,Givechev, Ivan,Naydenova, Emilia
, p. 1581 - 1592 (2020/11/23)
One of the potent somatostatin analogs, BIM-23052 (DC-23-99) d-Phe-Phe-Phe-d-Trp-Lys-Thr-Phe-Thr-NH2, has established in vitro growth hormone inhibitory activity in nM concentrations. It is also characterized by high affinity to some somatostatin receptors which are largely distributed in the cell membranes of many tumor cells. Herein, we report the synthesis of a series of analogs of BIM-23052 containing halogenated Phe residues using standard solid-phase peptide method Fmoc/OtBu-strategy. The cytotoxic effects of the compounds were tested in vitro against two human tumor cell lines—breast cancer cell line and hepatocellular cancer cell line, as well as on human non-tumorigenic epithelial cell line. Analogs containing fluoro-phenylalanines are cytotoxic in μM range, as the analog containing Phe (2-F) showed better selectivity against human hepatocellular cancer cell line. The presented study also reveals that accumulation of halogenated Phe residues does not increase the cytotoxicity according to tested cell lines. The calculated selective index reveals different mechanisms of antitumor activity of the parent compound BIM-23052 and target halogenated analogs for examined breast tumor cell lines. All peptides tested have high antitumor activity against the HepG2 cell line (IC50 ≈ 100?μM and SI > 5) compared to breast cells. This is probably due to the high permeability of the cell membrane and the higher metabolic activity of hepatocytes. In silico docking studies confirmed that all obtained analogs bind well with the somatostatin receptors with preference to ssrt3 and ssrt5. All target compounds showed high hydrolytic stability at acid and neutral pH, which mimic physiological condition in stomach and human plasma.
